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Background: Tinnitus is a symptom of an underlying medical condition that is 
associated with hearing loss in humans. It is a subjective disease where patients 
hear voices that others cannot hear. Increase in noise pollution, growing 
development of communication devices, and the long-ranging 8-year war in our 
country have further accelerated the spread of this disorder. Given that no 
definitive medical or surgical treatment has been confirmed for this condition, 
new research to improve treatment options is urgent. 
 
Aim: The purpose of this study was to assess the effect of a formulation prepared 
from Salvia hydrangea, Citrus aurantium, Lipia Citriodora, and elm bark on the 
status of tinnitus. 
 
Methods: In this single-blind clinical trial, 144 patients with tinnitus were 
selected based on pre-defined inclusion criteria and then randomly divided into 
3 groups: herbal formulation, cinnarizine, and placebo groups, where the 
frequency and intensity of tinnitus was measured based on the Tinnitus Handicap 
Inventory (THI) and Visual Analogue Scale (VAS) criteria before and on 28 and 
56 days post treatment. Data were analyzed by the statistical software SPSS 
version 16, repeated measurement, one-way, and X2 for comparison within and 
among groups, with the significance level set at p < 0.05. 
 
Results: comparably, tinnitus based on THI criteria differed among the 3 groups 
on 28 and 56 days of intervention, where the difference was statistically 
significant (p < 0.05). This difference was more significant between the 
cinnarizine and placebo groups. The mean severity of tinnitus, based on the VAS 
score, differed among the three groups on 28 and 56 days after intervention, 
although the difference was not statistically significant. 
 
Conclusion: Herbal formulation was effective on tinnitus alleviation, but its 
effect was not superior to that of conventionally used chemical drug cinnarizine. 
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Introduction 
The function of the auditory system is to convert 
voice and to detect the environmental signs (1). 
Tinnitus is a symptom of an underlying medical 
condition of ear that is associated with hearing loss. 
(2). James Hall (University of Florida) defines 
tinnitus as an illusory sense of sound that may not 
be disturbing because of a person’s activities, but 
may cause discomfort and insomnia to the patient, 
especially when the patient is alone and at nights 
(3). The growth of industrial societies, increase in 
noise pollution, the growing development of 
electronic communications, and the long-ranging 
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8-year war in our country have accelerated the 
spread of this disease (4). The prevalence of this 
phenomenon is estimated to be 3–30% (5). In 
America alone, 40 million people suffer from 
tinnitus. Of these, 12 million people are severely 
affected, with association of tinnitus reported in 2 
million of them. These problems affect the 
patients’ quality of life through depression and 
sleep disorders (3). Some ototoxic substances and 
drugs such as furosemide, acetazolamide, 
salicylates, alcohol, glycosylated antibiotics, 
mercury, gold, and lead are also implicated in the 
incidence of tinnitus. Thyroid diseases, 
hyperlipidemia, lack of vitamin B12, psychiatric 
disorders, fibromyalgia, ear diseases such as 
Meniere, head trauma, and multiple sclerosis may 
also contribute to tinnitus development (2, 6). As 
no definitive medical or surgical treatment has 
been approved for tinnitus and most efforts are 
focused on the psychological match and 
normalization of the buzzing sound as important 
factors of the disease adversely influencing the 
quality of life of the affected people, new research 
to improve treatment options and to find a proper 
solution remains inevitable (7). As a possible 
remedy, the use of complementary and alternative 
medicine (CAM) is growing popularity in many 
parts of the world and in European countries. In 
addition, most people use different products of this 
medicine with or without brochures for the 
treatment of tinnitus (8).  
Cinnarizine (25 or 75 mg pills) is an antihistamine 
drug which can inhibit H1 histamine receptors. It 
also inhibits calcium channels, vascular smooth 
muscle contraction, as well as the activity of the 
vestibular system. The side effects of this drug 
include drowsiness, concentration loss, 
gastrointestinal disorders, and anticholinergic 
complications such as visual disturbances, dry 
mouth, urinary retention, and headache. A 
formulation of herbs “Salvia hydrangea, Citrus 
aurantium, Lipia citriodora, and elm bark” is 
traditionally used by the citizens of Birjand for 
tinnitus treatment. The report of pleasant 
experience of patients when using this 
formulation has encouraged researchers to 
conduct further scientific research in this regard. 
The plant “Salvia hydrangea” is a mint plant, with 
anti-inflammatory, analgesic, antispasmodic, and 
anti-bloating properties (9). 
Citrus aurantium is the blossom of orange tree 
that is used as a drug. The most important 
medicinal properties of Citrus aurantium include 
its impact on the nervous system as a sedative and 
anti-anxiety compound.  
The pharmacological effect of elm bark is greater 
than that of its leaves. The leaves and bark of elm 
have sweating and diuretic properties, and their 
medicinal properties help relieve ear pain (9, 10)  
This study aimed to assess the impact of four 
drugs including Salvia hydrangea, Citrus 
aurantium, Lipia citriodora, and elm bark on the 
frequency and intensity of tinnitus. 
 
Methods 
In this single-blind clinical trial, 144 patients were 
selected from among patients referring for ear, 
nose, and throat disorders, in the clinic of Imam 
Reza Hospital (Birjand, Iran) who were diagnosed 
with tinnitus and the associated criteria.  
Before participation in this study, written 
informed consent obtained from each participant 
and/or their legal representative. 
Inclusion criteria of study subjects were 
willingness to participate in the study, age of 17–
70 years, and suffering from tinnitus for more than 
4 months. Exclusion criteria of the study subjects: 
Presence of otitis media, ear tumor, deformity 
within the ear, use of ototoxic drugs such as 
gentamicin, ear surgery, pregnancy, breastfeeding 
or being on birth control pills, history of extensive 
surgery or blood transfusion in the previous 
month, kidney failure, history of stroke or thyroid 
disease, otosclerosis, addiction to drugs or 
alcohol, and occupational exposure to noise.  
The included patients were divided into 3 groups 
based on random blocking: (a) receiving 
cinnarizine, (b) receiving herbal formulation 
(Salvia hydrangea, Citrus aurantium, Lipia 
citriodora, and elm bark), and (c) placebo. 
Cinnarizine tablet (25 mg; Osveh Co., Tehran, 
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Iran), formulated in sealed packages (4 g of each 
herb and 12 g of elm bark) with a cup and recipe 
of herbal tea (5 g of the mixed herb powder in a 
cup of boiled water three times a day before each 
meal), and placebo in the form of gelatin capsules 
containing starch were prescribed for 28 days. The 
intervention was discontinued with the control of 
patients’ tinnitus, but, in patients who failed to 
respond effectively, (Tinnitus Handicap 
Inventory, THI>30), the intervention was 
extended for another 28 days. Data collection was 
based on THI and Visual Analogue Scale (VAS) 
criteria before and on 28 and 56 days post 
intervention. THI criteria, based on the ear 
audiology registry center (11), consisted of 25 
questions with three levels of responses: Yes 
(score 4), Sometimes (score 2), and No (zero), by 
which the degree of tinnitus was measured. Thus, 
the minimum and maximum of THI questionnaire 
ranged from 0 to 100. In the qualitative 
classification, the scores 0–16 were considered as 
“absence of defect”, the scores 18–36 as “minor 
defect”, the scores 38–56 as “moderate defect”, 
the scores 58–76 as “severe defect”, and the scores 
78–100 as “catastrophic failure”. The validity and 
reliability of the aforementioned criteria had been 
confirmed in numerous national (12) and foreign 
studies (13).  
VAS criterion measures the severity of tinnitus 
and includes the agreed features expressible from 
0 to 10 according to the patient’s imagination. The 
zero score indicated the minimum severity of 
tinnitus, while score 10 revealed the maximum 
severity of tinnitus. This criterion has been used 
in national and foreign studies to measure the 
severity of tinnitus (12, 13). 
The patients were required to avoid OTC drugs, 
except for unavoidable cases, such as colds, 
headaches, or heartburn. They were also requested 
to avoid using drugs and dietary supplements such 
as Ginkgo, zinc, and vitamin B12, which directly 
affected the treatment of tinnitus. The data were 
analyzed by statistical software SPSS version 16, 
specifically through one-way, repeated 




Of the 144 patients with tinnitus who enrolled in 
this study, data of 138 patients were analyzed. Six 
patients were excluded from the study as their 
tinnitus was controlled after 28 days of 
intervention. The mean age of the participants was 
48.73±14.77; 64 (46.4%) of the patients were 
male and 74 (53.6%) were female; and the mean 
duration of patients’ tinnitus was 3 ± 1.35 years. 
No significant difference was noted in these items 
between the three groups (Table 1). 
Based on the THI criteria, the comparison of the 
mean severity revealed no significant difference 
before the intervention, though significant 
difference was noted after 28 and 58 days of 
intervention. Tukey’s test showed that the 
difference was significant at 28 days of 
intervention between the cinnarizine and placebo 
groups and after 56 days of intervention between 
the cinnarizine and placebo groups along with the 
formulation and placebo groups. However, no 
significant difference was noted between the 
results of the formulation and cinnarizine groups. 
Significant difference was observed within the 
groups at different times (Table 2). Based on the 
VAS criteria, the mean severity of tinnitus showed 
no significant difference among the three groups 
before the intervention, with differences after 28 
and 56 days after the intervention, although the 
difference between the groups was not significant. 
However, the difference in the intensity of tinnitus 
was statistically significant within the groups at 
28 and 56 days after treatment (Table 3). Based on 
the qualitative categorization, 6 patients (0.13) 
suffered from severe tinnitus and 3 (6.5%) from 
catastrophic failure in the cinnarizine group 
before intervention, but no patient reported severe 
or catastrophic defect after 28 days. In the herbal 
formulation group, 10 patients (21.7%) suffered 
from severe tinnitus, 2 (4.3%) from catastrophic 
failure before the intervention, and 3 (6.5%) had 
severe defect, but no patient experienced 
catastrophic failure after 28 days, while 1 patient 
(2.2%) showed severe defects after 56 days. In the 
placebo group, 11 patients (23.9%) suffered from 
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severe tinnitus, 1 patient (2.2) experienced 
catastrophic failure before the intervention, and 2 
patients (4.3%) showed severe tinnitus, but no 
patient showed catastrophic failure after 28 days 
although 1 patient (2.2%) reported severe tinnitus 
56 days after the study (Table 4). 









Age (year) 51.13±14.25 48.8±14.02 47±15.97 0.7 
Duration of tinnitus (year) 2.73±1.35 2.39±1.14 2.89±1.47 0.4 
Gender  
Male 21 (%45.7) 21 (%45.7) 22 (%47.8) 
0.9 
Female 25 (%54.3) 25 (%54.3) 24 (%52.2) 
 
Table 2. Comparison of THI score (Mean±SD) of cinnarizine, herbal formulations, and placebo,  






28 days after 
intervention  
(Mean±SD) 





Cinnarizine 51.30±12..43 36.26±6.08 31.23±9.64 p= 0.01 
Herbal 
formulation  
50.95±13.04 39.65±11.53 32.02±10.66 p= 0.01 
Placebo 49.08±12.59 41.84±8.15 38.52±8.90 p= 0.01 
One way  p= 0.6 p= 0.01 p= 0.001  
 
Table 3. comparison of VAS score (mean and SD) of Cinnarizine, herbal formulations, and placebo, 






28 days after 
intervention  
(Mean±SD) 





Cinnarizine 5.06±2.33 4±1.46 3.34±1.30 p= 0.001 
Herbal 
formulation  
5.21±2.14 4.36±1.81 3.78±1.63 p= 0.001 
Placebo 4.80±2.56 4.26±1.67 3.80±1.98 p= 0.001 
One way  p= 0.6 p= 0.5 p= 0.3  
 




28 days after 
intervention  
56 days after 
intervention  
frequency  percent frequency  percent frequency  percent 
Cinnarizine 
No handicap  - - - - 4 8.7 
Mild handicap 5 10.9 27 58.7 29 63 
Moderate 
handicap  
32 61.6 19 41.3 13 28.3 
Sever handicap  6 13 0 0 0 0 
Catastrophic 
handicap 
3 6.5 0 0 0 0 
Herbal 
formulation  
No handicap  - - - - 4 8.7 
Mild handicap 7 15.2 21 45.7 29 6.3 
Moderate 
handicap  
27 58.7 22 47.8 12 26.1 
Sever handicap  10 21.7 3 6.5 1 2.2 
Catastrophic 
handicap 
2 4.3 0 0 0 0 
Placebo 
No handicap  - - - - 0 0 
Mild handicap 6 13 21.7 10 21 45.7 
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28 60.9 34 73.9 24 52.2 
Sever handicap  11 23.9 2 4.3 1 2.2 
Catastrophic 
handicap 
1 2.2 0 0 0 0 
 
Discussion 
Several studies have suggested diverse drugs, 
such as carbamazepine, gabapentin, 
cinnarizine, and herbal compounds, such as 
Ginkgo biloba, for reducing the severity of 
tinnitus. However, the recent systemic and 
meta-analysis studies do not report any 
significant effect of these drugs or herbs on 
tinnitus, especially on the complications and 
possible risks. The findings on the efficacy of 
various medicinal herbs on tinnitus are diverse 
and sometimes contradictory. For example, 
numerous studies have reported the 
effectiveness of Ginkgo biloba in treatment of 
tinnitus (14). According to the results of the 
current study, the mean intensity of tinnitus 
(THI criteria) showed significant difference 
after 28 and 56 days of intervention, with the 
cinnarizine and herbal formulation groups 
showing better control over tinnitus as 
compared to the placebo group. The clinical 
trial of Choi et al. (7) on the impact of 
tympanic dexamethasone and placebo (saline) 
revealed that the extent of tinnitus improved in 
both groups, based on the THI criteria, but 
these changes were not statistically significant 
(p < 0.05), which is dissimilar to our result. 
Coelho et al. (5) study on the impact of dietary 
supplement and placebo showed that tinnitus 
was negligible in both groups, based on the 
THI criteria where these changes were 
statistically significant (p = 0.16 in the zinc 
group and p = 0.06 in the placebo group), 
which remains inconsistent with our study. 
Majd examined the mean scores of THI 
criteria between the gabapentin and placebo 
group and demonstrated better medical effect 
of gabapentin on tinnitus, which is in 
accordance with our results (12). According to 
ENTs’ and neurologists’ opinion, who 
consider tinnitus a multidisciplinary issue, the 
similar efficacy of cinnarizine and herbal 
formulation can be attributed to the nature of 
the disease, which is a subjective symptom 
where patients’ experience of the intensity and 
the frequency of the disturbance is different. 
The tolerance of patients is also different 
under psychological disturbances.  
Our results revealed that the severity of 
tinnitus was similar across the three groups 
before the intervention, according to the VAS 
scale and that it reduced similarly at 28 and 56 
days of the intervention, though the difference 
was not statistically significant. In the 
formulation group, 10 patients (21.7%) 
suffered from severe defects and only 1 patient 
(2.2%) had severe defect at the end of the 
study, suggesting 19.5% reduction in the 
severity of tinnitus. Our research is consistent 
with that of Berj et al. (15) on the effect of 
transcutaneous electrical nerve stimulation, 
which indicated 15% reduction in tinnitus on a 
numerical rating scale. 
Conclusion 
Our results indicated that herbal formulation in 
comparison with chemical drug and 
cinnarizine had the same effect on controlling 
tinnitus and it can replace them without any 
side effects. It is therefore recommended that 
the THI questionnaire be completed several 
times and its mean be analyzed before 
prescription, considering that tinnitus is a 
mental symptom and the emotional-mental 
state of patients varies at different occasions, 
which may affect the diagnosis. 
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